The ocular adnexa include the eyelids, conjunctiva, lacrimal apparatus, and orbital soft tissue. One percent of all lymphomas and approximately 8% of all extranodal lymphomas arise in the ocular adnexa and their incidence is increasing. Reactive lymphoid hyperplasia comprises 16% of all lymphoproliferative tumors of the ocular adnexa. The relative frequencies of ocular adnexal lymphoma presentation are in the orbit, 37%; conjunctiva, 29%; lacrimal apparatus, 20%; and eyelid, 14%. The most frequent primary lymphoma types of the ocular adnexa are extranodal marginal zone lymphoma, 62%; follicular lymphoma, 17%; and diffuse large B-cell lymphoma, 10%. The eyelids show the highest proportion of secondary lymphoma involvement, 49% of all eyelid lymphoproliferative lesions, compared with 24% in all ocular adnexa. The specific aspects of the site, histologic, immunohistochemical, cytogenetic, and molecular findings of the most relevant lymphoma types occurring in the various parts of the ocular adnexa will be discussed in relation to clinical parameters and relevance for therapy choice. Furthermore, the implications of the updated version of the World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues in relation to ocular adnexal lymphoma are reviewed.
O cular adnexal lymphoproliferative disease (OALD) is a general term encompassing the spectrum of lymphoproliferative tumors of the ocular adnexa (OA). The OA comprise the eyelids, conjunctiva, lacrimal apparatus, and orbital soft tissue. Benign OALD is a reactive lymphoid hyperplasia (RLH) of polyclonal small B cells and T cells. Theoretically, any type of lymphoma can involve the OA. Malignant lymphomas are classified according to the presumed cell of origin as defined by the World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues, 1 of which the updated version is yet to be published at the time of writing this review.
2 Lymphomas can be divided into 2 major groups: Hodgkin lymphoma and nonHodgkin lymphoma (NHL). Because Hodgkin disease of the OA is extremely rare, it will not be discussed here. Primary ocular adnexal lymphoma (OAL) is defined as a lymphoma of the OA without evidence of concurrent systemic lymphoma and no prior history of lymphoma. Primary OAL should be staged according to the TNM classification devised for OAL (Table 1 ) because the TNM-based staging system better predicts outcome in OAL than the Ann Arbor system.
regional peculiarities
The orbital bone and (peri-) ocular connective tissues are derived from neural crest cells (ie, mesectoderm not mesoderm). Although the lacrimal gland arises from a thickening of the ectoderm of the superior conjunctival fornix, the mesenchymal cells that surround the point of epithelial budding are also of neural crest origin. This exceptional mesenchymal environment can be expected to be of relevance to the specific etiologic, molecular genetic, and clinical features of OAL that, as will be discussed below, differ from other extranodal NHL.
In the nondiseased lacrimal gland, IgA-producing plasma cells account for approximately 50% of all lymphoid cells. T cells, representing the second most common cell type, are located predominantly in small lymphocytic foci and singly in the interstitium of the lacrimal gland. Conjunctival lymphoid tissue can be observed in the healthy palpebral conjunctiva, more pronounced in the upper than in the lower lid. It occurs both as diffuse lymphocytes and IgA-producing plasma cells located in the substantia propria. Additionally, approximately 60% of nondiseased conjunctival sacs have organized lymphoid accumulations in the substantia propria. The epithelium of the lacrimal gland tubules and acini, along with the conjunctival crypts, expresses lysozyme and the IgA secretory component. The conjunctiva and lacrimal gland thus belong to the mucosa-associated lymphoid system (MALT), also called eye-associated lymphoid tissue (EALT). Lymphocytes recirculate to the EALT via high endothelial venules (inflow) and lymph vessels (outflow) through a complex interplay of chemokines, chemokine receptors, and integrins. The nonconjunctival side of the eyelids contains disperse inflammatory cells, mainly CD4-positive T cells, macrophages, and dendritic cells of the skin. The skin of the eyelids contains lymph vessels, comparable to skin at other sites. In contrast to the eyelid, conjunctiva, and lacrimal gland, the soft tissues of the orbit and its contents have long been considered extralymphatic sites that do not contain lymph vessels or lymphoid cells in a healthy state. However, using an immunohistochemical set of markers specific for lymphatic endothelium, it recently was revealed that intraconal vascular structures covered with lymphatic endothelium are present in the orbit of fetus and adults (Fig. 1) . The exact function and drainage routes of such lymphatic vasculature have yet to be determined.
Apart from the genetic changes, the development and progression of B-NHL is known to also depend on interactions with T1b Palpebral conjunctiva ± fornix ± caruncle T1c Bulbar and nonbulbar conjunctival involvement T2 Lymphoma with orbital involvement ± any conjunctival involvement T2a Anterior orbital involvement but no lacrimal grand involvement ± conjunctival disease T2b Anterior orbital involvement with lacrimal gland involvement ± conjunctival disease T2c Posterior orbital involvement ± conjunctival involvement ± any extraocular muscle involvement T2d Nasolacrimal drainage system involvement ± conjunctival involvement but not including nasopharynx T3 Lymphoma with preseptal eyelid involvement ± orbital involvement ± any conjunctival involvement the tumor microenvironment that are mediated/directed by chemokines, chemokine receptors, and integrins. The expression profile of motility and adhesion molecules in OAL have recently been described to differ from that in lymphomas of the secondary lymphoid organs. 4 These findings suggest that the malignant cells in OAL likely undergo a dynamic process of trafficking involving egress into the blood (directed by sphingosine-1 phosphate receptors) and homing back to the extranodal tissues (directed by chemokine CXCR4 and its receptor CXCL12 and mediated by α4 integrin) where an element of retention may occur (via chemokine CXCR5 and its receptor CXCL13). Analysis of different anatomical variants of OAL in this study showed no association between chemokine (receptor) expression and location in the eyelid, conjunctiva, or orbit.
epidemiology
Ocular adnexal lymphoproliferative diseases include benign and malignant disease such as RLH 5 and lymphoma based on histopathology, immunophenotype, and molecular features. Ocular adnexal lymphoma represents malignant lymphoid neoplasms, which can develop as primary or secondary tumor manifestations. One percent to 2% of all lymphomas and approximately 8% of all extranodal lymphomas arise in the OA and the incidence is increasing. 6 In Europe there is a consistent overall increase in incidence of NHL. An estimated 5% of NHL patients develop secondary OA involvement during the course of their disease. Lymphoid tumors comprise 10% to more than 20% of orbital mass lesions in different series, and lymphoma is the most common orbital malignancy. 7 Likewise, lymphomas involving the conjunctiva are relatively common.
8 Ocular adnexal lymphoma is primarily a disease of older adults (peak age 65 years) with a slight female preponderance.
To gain insight into the relative frequencies of the types and location of biopsied OA lymphoid disease, the diagnoses and location of 264 consecutive lymphoproliferative lesions diagnosed between 1987 and 2016 in the department of pathology of the Erasmus University Medical Center were evaluated (Table 2 ). In this series the most frequent OA presentation was in the orbit, 37%; followed by conjunctiva, 29%; lacrimal apparatus, 20% (only 3 cases involved the lacrimal sac); and eyelid, 14%. These updated figures do not differ significantly from an earlier published review.
9
Reactive lymphoid hyperplasia is diagnosed in about 16% of OALD (Fig. 2) . The most frequent primary OAL diagnosis is extranodal marginal zone lymphoma (ENMZL) in 42% of all lymphoid lesions and 62% of all primary OAL (Table 2, Fig. 3,  Fig. 4 ). The highest frequency of ENMZL/MALT lymphoma is observed in the conjunctiva in 70% of all primary lymphoid conjunctival lesions. Primary marginal zone lymphomas of the orbit (50%) should be designated ENMZL, as no MALT tissue is supposedly involved in the genesis of these lesions. One case of gastric MALT lymphoma secondarily involved the orbit, but the conjunctiva and lacrimal gland may also show secondary involvement of distant MALT lymphoma (Table 2) . 10 The different OA structures show a distinctly different disease spectrum. The eyelids show the highest proportion of secondary lymphoma involvement (49% of all eyelid lymphoproliferative lesions), and this probably also explains the most varied list of 13 different diagnostic entities, including T-cell lymphoma (Table 2 ). This seems to separate eyelid lymphoid lesions clearly from the other ocular adnexa. For the conjunctiva, lacrimal apparatus, and orbit (37) 37 (14) 53 (20) 76 (29) there is approximately 80% primary lymphoid lesions and 20% secondary involvement (Table 2) .
10
The second most frequent primary OAL diagnosis is follicular lymphoma (FL, Fig. 5 ), 17% of all OAL, closely followed by diffuse large B-cell lymphoma (DLBCL, Fig. 6 ) at 10%. Mantle cell lymphoma was diagnosed in 4% of primary lesions. Other primary diagnoses are small lymphocytic lymphoma, 4%; lymphoplasmacytic lymphoma, 2%; and 1 case of Burkitt lymphoma. Almost all (90%) ENMZL are primary OAL. 10 The most common secondary lymphoma subtype is mantle cell lymphoma with 22% of all secondary lymphomas, followed by ENMZL (including MALT lymphoma), 17%; chronic lymphocytic leukemia (CLL), 16%; FL, 14%; DLBCL, 11%; and lymphoplasmacytic lymphoma, 6%. Other secondary lymphoma diagnoses are given in Table 2 .
reactive lymphoid hyperplasia
Reactive lymphoid hyperplasia is diagnosed in about 16% of OALD and is most common in the lacrimal gland (48% of all primary lymphoid lesions of the lacrimal gland, Table 2 ). The diagnosis of RLH is made based on morphology ( Fig. 2A ) in the absence of a monotypical B cell population by immunohistochemistry (Figs. 2B-F) or preferably by exclusion of a monoclonal B cell population by flow cytometry and/or molecular techniques. No lymphoepithelial lesions should be present (Fig. 2G) . It is widely recognized that the generally hypocellular lymphoid cell-poor orbital pseudotumors (idiopathic orbital inflammation) and RLH represent distinct entities. 5 Reactive lymphoid hyperplasia comprises 2% of all lesions of the orbit, representing 7% of all inflammatory lesions.
7 With the advent of multimodal lymphoma diagnostics, including flow cytometry and molecular testing, there has been a shift in diagnostic patterns with previously thought benign RLH being reclassified as ENMZL. 5 The designation of atypical lymphoid hyperplasia may be used for indeterminate lesions where the amount of tissue available or the combined results of flow cytometric or molecular investigations are inconclusive. The use, however sparse, of this diagnostic category can guide management and follow-up. Reactive lymphoid hyperplasia may mimic early IgG4-related disease and has been documented in single cases to develop into the typical sclerotic lesions of this disease over a period of 20 years.
11 Immunohistochemical staining for IgG and IgG4 is therefore recommended in all cases of RLH (Figs. 2H-I).
enmZl/malt lymphoma
The deep orbital tissue is not considered lymphoid tissue, whereas the lacrimal gland, the conjunctiva, and the lacrimal sac are considered as functional MALT. 12, 13 Ophthalmic pathologists therefore know that MALT lymphoma is not synonymous with ENMZL and is characterized by mucosal location and lymphoepithelial lesions. Extranodal marginal zone lymphoma may arise in MALT or reactive tertiary lymphoid tissue acquired through chronic antigenic stimulation because of persistent inflammation or infection as exemplified by Helicobacter pylori infection in patients with gastric MALT lymphoma. Likewise, Chlamydia psittaci infection has been associated with ENMZL of OA.
14 C. psittaci is living and infective both in conjunctival tissue and peripheral blood mononuclear cells. In vitro isolation of this microorganism from patients with ENMZL of OA fulfills Koch's second postulate, enhancing the specific relationship between C. psittaci and lymphomagenesis in this anatomical region. However, epidemiologic studies analyzing association between C. psittaci and OAL demonstrated marked geographic and methodical differences.
15 Gastric H. pylori positivity has been documented in 32% of ENMZL of OA patients; none of these patients responded with lymphoma regression upon H. pylori eradication therapy. 16 Direct infection of the orbit by H. pylori has been suggested but appears highly implausible. Extranodal marginal zone lymphoma have consistently been associated with several autoimmune disorders. The exact mechanism of lymphomagenesis in the context of autoimmunity is largely unexplained. An interesting association has occasionally been observed between IgG4-related disease and ENMZL of OA.
17 On the other hand, documented long-term IgG4-related disease does not necessarily develop into lymphoma.
ipsilateral and/or contralateral regional lymph nodes and to more distant sites. Clinical features are of a space-occupying mass that is painful in less than 10% of patients. Few patients have B symptoms such as fever, night sweats, or weight loss. The duration of symptoms at presentation ranges from a few months to 3 years. A resection or biopsy yields white to salmon pink fleshy tissue.
Ocular adnexa MALT/ENMZL are composed of small-to medium-sized cells with round or indented nuclei, clumped chromatin, inconspicuous nucleoli, and inconspicuous to moderately abundant cytoplasm (Fig. 3A) . Other than lymphoepithelial lesions more easily identified using keratin stain (Fig. 4) , marginal zone involvement (Figs. 3B-D) , and follicular colonization (BCL2-positive staining of the follicle, Fig. 3E ), most of the findings are rather nonspecific for distinction from other small B lymphomas. Plasmacytoid differentiation is frequent in ENMZL of OA. Extranodal marginal zone lymphoma of OA lack specific markers of other small-cell lymphomas and are positive for B lineage markers (Fig. 3C) and BCL2 (Fig. 3E ). There is a low proliferation rate (Fig. 2F) . In current practice, there is no distinctive positive immunologic marker for ENMZL 1 : they are negative for CD23, CD5, CD10 (Fig. 3G) , BCL6 (Fig. 3H) , and CyclinD1 (Fig. 3I ). IRTA1 has been described as a suitable immunohistochemical marker for the positive identification of ENMZL; however, the only commercially available antibody to date has been reported to be less well suited for identification of ENMZL of OA with IRTA1 with positive staining in only 66% of cases.
18 IRTA1 does not distinguish hyperplasia from ENMZL. 19 The combination of IRTA1 with T-bet may increase the diagnostic sensitivity for marginal zone proliferations, although T-bet may also be expressed in CLL, DLBCL, and hairy cell leukemia.
20 At a molecular level there is clonal rearrangement of immunoglobulin heavy chain and light chain, which is essential to make the distinction between RLH and lymphoma. On the genetic and molecular level different mechanisms can be observed in ENMZL of OA; aneuploidy, translocations, deletions, and mutations mostly affect or target genes encoding for regulators of NF-κB. Trisomy of chromosomes 3, 12, and 18 are frequent in all ENMZL, but gain of chromosome 6, including trisomy, is more specific for ENMZL of OA. 21 Translocations occur relatively infrequently in ENMZL of OA when compared with MALT lymphoma at other sites. 21, 22 Extranodal marginal zone lymphoma of OA translocations may include t(11;18)(q21;q21) in 0-15%, t(14;18)(q32;q21) in 0-38%, t(1;14)(p22;q32) in 0-3%, and t(3;14)(p13;q32) in 0-20% (reviewed by Zhu et al 22 ), along with 1 published case each of t(6;14)(p21.1;q32.3), t(14;17)(q32.33;p13.1), and t(5;11)(q33;p11.2). These translocations target the MALT1, BCL10, or FOXP1 genes. The different incidence of the translocations in MALT-type lymphomas from distinct geographic and anatomical sites is probably linked to specific prelymphomatous conditions (geographical, environmental, embryologic/developmental, or other unknown conditions) that influence neoplastic transformation. TNFAIP3, a tumor suppressor, is inactivated by promoter methylation, mutations, and/or deletions in about 15-30% of ENMZL of OA.
23 Deletion of chromosome 6q23 affects the A20 gene, 21 which may also be mutated 22 and is affected in about 30% of ENMZL of OA cases. Activating mutations of MYD88, a factor physiologically linking toll-like receptor signaling to NF-κB activation, have been described in about 0-7% of the cases along with occasional mutations in the BIRC3 and PRDM1 genes, all affecting the NF-κB pathway. In case of MYD88 L265P mutation, a lymphoplasmacytic lymphoma (morbus Waldenström) should be considered because 80-90% of lymphoplasmacytic lymphoma harbor this mutation. 24 Mutations in MYD88 have reportedly been associated with an inferior disease-free survival in ENMZL of OA. 23 MicroRNA expression patterns have also been described to relate to the NF-κB pathway in ENMZL of OA. 25 The updated WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues is not expected to pose any changes in ENMZL diagnosis and classification.
2
In some cases incisional biopsy or surgical resection may serve as therapy for ENMZL of OA; however, attempts for complete resection should not be made because this does not influence survival and can lead to severe complications. A "wait and watch" strategy can be safely proposed for elderly or frail patients with little symptoms. Recently, the effectiveness of primary antibiotic treatment of ENMZL of OA directed at eradication of C. psittaci was reviewed. 26 The median follow-up for these studies was 25 months, and both C. psittaci-positive and C. psittaci-negative patients responded. Complete remission (CR) was achieved in 18% of patients out of 131 patients reported. The combined numbers of CR and partial remission (PR) account for an overall remission rate of 45% ENMZL of OA. Although lacking longterm follow-up information, these results do not seem inferior to the outcome reported for chemotherapy and radiotherapy, suggesting that upfront doxycycline is a reasonable and effective treatment proposal for patients with stage I C. psittaci-positive ENMZL of OA before considering more aggressive strategies.
27
Resistance to C. psittaci eradication has not been described to be related to MALT1 translocation. Most OAL are localized (stage I) at presentation, and radiation therapy provides excellent local control, 28 with 4-year relapse rates of 20-25%. However, 45% of patients develop late sequelae of radiation therapy (especially cataract) and 25% of patients experience side effects WHO grade 3-4. For more advanced disease stages, chemotherapy with chlorambucil with or without prednisolone yields excellent response rates with a 5-year relapse-free survival of 60%. The use of upfront additional anthracyclin-based chemotherapy does not show clinical advantages. The use of rituximab as a single agent is associated with short-lived responses. 29 Intralesional injections with rituximab or interferon alpha may be safe and active strategies for conjunctival MALT lymphomas, but long-term results remain to be confirmed. 29, 30 follicular lymphoma
For patients with FL of the ocular adnexa (OAFL), no etiologic or predisposing factors have been identified. However, low numbers of t(14;18)-positive B cells can be detected in healthy individuals, 31 and these B cells are reported to have biological features that are closely associated with the pathogenesis of the disease. What used to be called in situ follicular lymphoma is proposed to be renamed in situ follicular neoplasia in the updated WHO classification using the same criteria.
2 Ocular adnexal follicular lymphoma occurs most frequently in the orbit and conjunctiva but may involve all ocular adnexa (Table 2) .
32 Clinical features are of a space-occupying mass that is painful in over 20% of patients 32 (Fig. 5I) . Patients generally do not present with B symptoms. The duration of symptoms at presentation ranges from 1 month to 9 years.
32 Follicular lymphoma can present as primary ocular adnexal disease and secondary involvement in about one third of cases; it may be bilateral in up to 20% of cases.
32 Dissemination of OAFL mainly occurs to the regional lymph nodes and the salivary glands and may involve distant lymph nodes. Follicular lymphoma can transform to DLBCL in 3% of cases.
Follicular lymphoma are composed of uniform, densely packed follicles, which may coalesce, simulating diffuse areas (Fig. 5A) , with compression of interfollicular stroma and vessels, that can be highlighted by reticulin stain. The follicular population is uniformly atypical. Small cells (centrocytes) have cleaved, indented, angulated nuclei; large cells (blastic centrocytes) may be cleaved or noncleaved. In addition, variable large cells (centroblasts and immunoblasts) with vesicular nuclei containing 1 or 2 nucleoli, often adjacent to the nuclear membrane, can be found. Mitotic figures are less frequent in grade 1 and grade 2 FL than in figure 5 . Ocular adnexal follicular lymphoma of the conjunctiva. A, HE shows uniformly atypical lymphocytes forming densely packed follicles, with compression of interfollicular stroma. B, CD3 indicates T cells in the compressed interfollicular areas. C, CD20 stains the massive follicular expansion of atypical B cells. D, CD21 shows massively expanded regular dendritic cell meshworks. E, BCL2 uniformly stains the neoplastic B cells in the expanded follicle centers. F, MIB1 shows a slightly increased staining pattern (compared with the reactive follicles of Figs. 2F and 3F) . G, CD10 uniformly stainsRLH, which is reflected in low Mib1 staining (Fig. 5F) ; however, grade 3 FL may have a high mitotic rate. In general the prognosis of FL supposedly worsens with greater proportions of centroblasts. Follicular lymphoma grading is performed by estimating the average number of centroblasts per high power field (HPF) in 10 neoplastic follicles (grade 1, 0-5 centroblasts per HPF; grade 2, 6-15 centroblasts per HPF; grade 3A, >15 centroblasts per HPF) 1 ; grade 3B also contains more than 15 centroblasts but in addition the centroblasts form coalescent tumor areas without centrocytes. Because of the small size of the ophthalmic biopsies, formal grading is not always possible. Grade may be reported as low grade (1-2) and high grade (3A and 3B). In some institutions distinction is made between grade 3A and 3B for therapeutic strategy reasons. The interfollicular zone is typically composed of small reactive cells (Figs. 5A, B) . Follicular lymphoma are BCL2 and CD10 positive in 85% of cases (Figs. 5E, G) . Positive staining for BCL2 is quite specific versus pre-existent secondary germinal centers (Fig. 5E ). CD10 expression distinguishes this entity from other mature small B lymphomas. Follicular lymphoma also stain positive for BCL6 (Fig. 5H ) and show expansion, demarcated by follicular dendritic cell meshworks that stain positive for CD21 (Fig. 5D) , CD23, and CD35. However, these meshworks are usually compact and intact instead of demonstrating a more ragged aspect as in marginal zone lymphoma and mantle cell lymphoma.
On the genetic level t(14;18) translocation has been recognized as a genetic hallmark of FL, but additional genetic aberrations are required for the development of FL. Cytogenetic analyses of FL samples have revealed that they contain 4 to 6 additional genomic alterations on average, and 6q-, trisomy 7, trisomy 12, der (18), and +X are frequently observed. On the basis of the fluorescent in situ hybridization (FISH) results, 76% of all OAFL test t(14;18)-positive. 32 This genetic aberration results in the constitutive expression of BCL2 and confers a survival advantage to B cells. Recently, additional recurrent gene aberrations such as TNFRSF14, EPHA7, EZH2, CREBBP, EP300, MLL2, and MEF2B have been identified in FL at large. 33 Many of these mutations have been confirmed in OAFL. 34 Thus, unlike ENMZL, multiple pathways are involved in lymphomagenesis of FL. This is assumed to constitute a major reason for the clinical heterogeneity of the disease. A new prognostic model integrating gene mutations with clinical parameters has been proposed, but, although conceptually interesting, requires validation 35 ; in particular, relevance for OAFL needs to be established for the most prognostically important genes, ARID1A and TP53. Whether mutational analysis should be performed routinely for diagnostic, prognostic, or therapeutic purposes and whether it should be integrated with other pathological and clinical prognostic factors remains to be determined. The updated WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues has newly defined pediatric-type FL as a localized clonal proliferation with excellent prognosis where a conservative therapeutic approach may be sufficient.
2 This new entity is of limited relevance to OAFL because it occurs in children and young adults, rarely in older individuals. The molecular genetic hallmarks of this new entity are absence of BCL2, BCL6, and MYC rearrangements.
Most patients with OAFL stage I/II disease are treated with radiotherapy (usual dosage 30 Gy), which results in an 85% local disease control rate.
32 Distant relapse occurs in 6-50% of patients at a median follow-up of 7 years, and there is a 10-year overall survival (OS) rate of 83%. Interestingly, a significantly better disease-specific survival was found for patients with primary OAFL treated with radiotherapy only compared with patients receiving radiotherapy plus chemotherapy.
32 For stage III-IV OAFL, systemic chemotherapy is indicated following standard regimens currently used for nodal disease. Anthracycline-based regimens such as cyclophosphamide, vincristine, and prednisone or chlorambucil/cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone combined with rituximab (R-CVP or R-CHOP) are suitable for treating these patients. The overall median progression-free survival from the date of diagnosis was 5.3 years in a recent multicenter trial. The overall survival rates at 10 and 20 years were 60% and 15% (median overall survival, 11 years), respectively, for the entire patient group, whereas the 10-and 20-year disease-specific survival rates were 69% and 29% (median disease-specific survival, 20 years), respectively. The diseasespecific survival was not different in patients with primary, disseminated, and relapsed OAFL. (Table  2) . Diffuse large B-cell lymphoma is the third most common lymphoma subtype occurring in the ocular adnexa (Table 2) .
36 Patients usually present with a rapidly expanding tumor mass that is often unilateral and located mainly in the orbit. Thirty percent of patients experience pain or irritation. Patients may experience B symptoms.
Diffuse large B-cell lymphomas show diffuse effacement of normal architecture and are composed of large noncohesive cells, which make up over 50% of the population or are present in confluent foci. The usual appearance is large vesicular nuclei with multiple irregular eosinophilic nucleoli (Fig. 6A) . Diffuse large B-cell lymphomas stain positive for CD20 (Fig. 6C) ; however, in biopsies taken after treatment with rituximab this marker may be negative and alternative B cell markers such as CD79a and PAX5 should be employed. Usually there are few reactive T cells (Fig. 6B) .
Genome-wide expression profiling has revealed a number of features associated with an unfavorable clinical outcome. According to similarities to the putative cell of origin, OA DLBCL can be largely divided into 2 different groups: germinal center B-cell-like (GCB) DLBCL and activated B-cell-like (ABC) DLBCL 37 ; however, 15-30% of DLBCL cannot be classified definitively. Further investigations have revealed different activation pathways for the respective subtypes. Activated B-cell-like DLBCL have a poorer overall survival compared with GCB-DLBCL and respond less effectively to chemotherapy. Different immunohistochemical marker combinations can aid in discrimination between ABC-DLBCL and GCB-DLBCL. Several of these algorithms have been demonstrated to be predictive of survival. The most widely known "Hans classifier" composed of CD10 (Fig. concordance with the molecular classification. A combination of 5 immunohistochemical markers-GCTE1, CD10, BCL6, MUM1, and FOXP1-can achieve about 90% concordance with the molecular results, whereas others using either 3 or 5 markers have been proposed but have not been widely tested on independent patient cohorts. All these algorithms have been shown to have a high concordance. 38 The better understanding of the molecular pathogenesis of these 2 subgroups has led to the investigation of more specific therapeutic strategies to mitigate the worse outcome among those with ABC/non-GCB type DLBCL reported in most studies; prospective trials are ongoing to determine whether these therapies should be incorporated into clinical practice. For this reason, the revised WHO classification will require the identification of these 2 DLBCL subtypes.
2
The revised WHO classification also focuses on MYC alterations in DLBCL. MYC is rearranged in 5% to 15% of DLBCL, not otherwise specified (NOS) and is often associated with BCL2 and/or, less frequently, BCL6 translocation in the "double-hit" or "triple-hit" lymphomas that are included in the updated WHO classification in the new category of high-grade B-cell lymphoma (HGBL), with rearrangements of MYC and BCL2 and/or BCL6.
MYC protein expression is detected in a higher proportion of DLBCL (30-50%) and is associated with protein expression of BCL2 in 20% to 35% of cases. Often these tumors do not carry MYC/BCL2 chromosomal alterations and have been named "double-expressor lymphoma." A cutoff of 40% MYC-expressing cells can be used to define these cases. For BCL2 expression a cutoff of 50% is recommended (Fig. 6D) . Double expression of MYC and BCL2 proteins without gene aberrations should be considered a prognostic indicator in DLBCL, NOS but will not be assigned a separate category.
2 All large B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements need to be designated HGBL, with MYC and BCL2 and/or BCL6 rearrangements. Other cases that appear blastoid or cases intermediate between DLBCL and Burkitt lymphoma, but which lack a MYC and BCL2 and/or BCL6 rearrangement, should be designated HGBL, NOS. A consensus has not yet been reached to provide specific guidelines as to which large B-cell lymphomas should have fluorescence in in situ hybridization studies.
2 Testing for MYC, BCL2, and BCL6 rearrangements should always be contemplated in NOS cases and cases with a GCB phenotype. Diffuse large B-cell lymphomas with high-grade morphology or cases with more than 40% MYCpositive cells should also be tested for MYC, BCL2, and BCL6 rearrangements.
Epstein-Barr virus (EBV)-positive DLBCL generally occur in immunocompetent patients over 50 years old and have a worse prognosis than EBV-negative tumors. Epstein-Barr virus-positive DLBCL have also been recognized in younger patients who have a better survival. This new information has led to the proposal of a new entity of EBV-positive DLBCL, NOS.
2 In summary, current state-of-the-art diagnosis of DLBCL requires testing for determination of the subtype of DLBCL by molecular or immunohistochemical testing for ABC-or GCB-DLBCL. In cases of GCB-DLBCL or DLBCL, NOS additional testing for MYC and BCL2 immunohistochemistry and FISH is advisory. In ABC-DLBCL at least immunohistochemical testing for BCL2 and MYC expression is recommended, as positive cases indicate a worse prognosis. Epstein-Barr virus status can most reliably be determined by EBV-encoded RNA (EBER)-FISH.
The International Prognostic Index has been developed as a clinical tool for predicting outcome in DLBCL. Negative prognostic factors are an age at the time of diagnosis over 60 years, Ann Arbor stage III or higher, the involvement of more than 1 extranodal sites, elevated LDH serum level, and poor performance status. The treatment results of DLBCL have greatly improved with the introduction of the CHOP chemotherapy scheme and have further improved with the addition of rituximab (R-CHOP) to a 5-year OS of 60%. For patients younger than 60 years of age and with a high-risk profile, the addition of etoposide shows an improved outcome (R-CHOEP).
conclusions
The newly revised WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues mainly affects the diagnostic strategies in DLBCL of OA requiring the determination of ABCor GCB-DLBCL subtyping, MYC and BCL2 protein expression, and FISH for recognition of the new category of HGBL, with MYC and BCL2 and/or BCL6 rearrangements. Epstein-Barr virus-encoded RNA FISH should be performed to recognize the new category of EBV-positive DLBCL, NOS. Multimodal histopathological, immunophenotyping, and molecular genetic investigations are therefore essential to precisely diagnose and classify lymphoproliferative tumors of the OA and are important for identifying potential therapeutic targets and prognostic factors. Immunophenotyping can be performed using flow cytometry and immunohistochemistry. Flow cytometry is a rapid, quantitative procedure and allows multiple antigens to be evaluated on the same cell simultaneously, which aids in the identification of clonal lymphocyte populations. Immunohistochemistry requires more time to perform and quantitation is more subjective, but it allows for correlation of antigen expression with architecture and cytomorphology. Molecular genetic investigations may reveal additional diagnostic, prognostic, and potentially therapeutic relevant markers. Ideally the results of all these investigations should be discussed in a multidisciplinary team for an integrated diagnosis and management proposal. An cohesive report based on clinical, radiologic, pathologic immunologic, and molecular genetic investigations is the ultimate goal. 
